Latest Insider Transactions at Laboratory Corp Of America Holdings (LH)
This section provides a real-time view of insider transactions for Laboratory Corp Of America Holdings (LH). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of LABORATORY CORP OF AMERICA HOLDINGS to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of LABORATORY CORP OF AMERICA HOLDINGS's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 02
2022
|
Lance Berberian EVP, Special Advisor, Strategy |
BUY
Exercise of conversion of derivative security
|
Direct |
296
+2.0%
|
-
|
|
Feb 02
2022
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
236
-0.55%
|
$64,428
$273.18 P/Share
|
|
Feb 02
2022
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
766
+1.74%
|
-
|
|
Feb 02
2022
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
803
-5.29%
|
$219,219
$273.18 P/Share
|
|
Feb 02
2022
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,773
+15.44%
|
-
|
|
Feb 02
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
147
-1.52%
|
$40,131
$273.18 P/Share
|
|
Feb 02
2022
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+4.38%
|
-
|
|
Feb 02
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
41
-3.64%
|
$11,193
$273.18 P/Share
|
|
Feb 02
2022
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
116
+9.33%
|
-
|
|
Feb 02
2022
|
Judith C Seltz EVP, CHRO |
SELL
Payment of exercise price or tax liability
|
Direct |
76
-6.04%
|
$20,748
$273.18 P/Share
|
|
Feb 02
2022
|
Judith C Seltz EVP, CHRO |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+14.89%
|
-
|
|
Feb 02
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
144
-1.53%
|
$39,312
$273.18 P/Share
|
|
Feb 02
2022
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+4.5%
|
-
|
|
Feb 02
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
77
-19.64%
|
$21,021
$273.18 P/Share
|
|
Feb 02
2022
|
Amy B. Summy EVP, Chief Marketing Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
220
+35.95%
|
-
|
|
Feb 02
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
64
-1.16%
|
$17,472
$273.18 P/Share
|
|
Feb 02
2022
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
236
+4.1%
|
-
|
|
Feb 02
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
121
-1.81%
|
$33,033
$273.18 P/Share
|
|
Feb 02
2022
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
443
+6.22%
|
-
|
|
Feb 02
2022
|
Kerrii B Anderson Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+3.8%
|
-
|
|
Feb 02
2022
|
Peter M Neupert Director |
BUY
Exercise of conversion of derivative security
|
Direct |
771
+10.25%
|
-
|
|
Dec 15
2021
|
Dwight Gary Gilliland Director |
SELL
Open market or private sale
|
Direct |
500
-1.88%
|
$151,000
$302.28 P/Share
|
|
Dec 14
2021
|
Kerrii B Anderson Director |
SELL
Bona fide gift
|
Direct |
1,550
-2.6%
|
-
|
|
Nov 05
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
899
-12.59%
|
$246,326
$274.84 P/Share
|
|
Nov 05
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+21.97%
|
-
|
|
Nov 05
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
SELL
Payment of exercise price or tax liability
|
Direct |
899
-8.92%
|
$246,326
$274.84 P/Share
|
|
Nov 05
2021
|
Brian J Caveney EVP, Pres of ED, CMO & CSO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,010
+16.63%
|
-
|
|
Nov 01
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
898
-9.12%
|
$258,624
$288.78 P/Share
|
|
Nov 01
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+16.93%
|
-
|
|
Nov 01
2021
|
Glenn A Eisenberg Executive Vice President |
SELL
Payment of exercise price or tax liability
|
Direct |
4,034
-8.68%
|
$1,161,792
$288.78 P/Share
|
|
Nov 01
2021
|
Glenn A Eisenberg Executive Vice President |
BUY
Exercise of conversion of derivative security
|
Direct |
9,024
+16.27%
|
-
|
|
Nov 01
2021
|
Adam H Schechter President & CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
886
-6.66%
|
$255,168
$288.78 P/Share
|
|
Nov 01
2021
|
Adam H Schechter President & CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
2,007
+13.12%
|
-
|
|
Sep 15
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,500
-46.09%
|
$1,332,000
$296.78 P/Share
|
|
Sep 15
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+31.55%
|
$378,000
$84.86 P/Share
|
|
Aug 02
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
15
-1.46%
|
$4,455
$297.61 P/Share
|
|
Aug 01
2021
|
Peter J Wilkinson SVP, Chief Accounting Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
50
+4.65%
|
-
|
|
Jun 07
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
4,500
-46.22%
|
$1,197,000
$266.56 P/Share
|
|
Jun 07
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,500
+31.61%
|
$378,000
$84.86 P/Share
|
|
May 06
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Open market or private sale
|
Direct |
2,500
-24.17%
|
$690,000
$276.55 P/Share
|
|
May 03
2021
|
Jean Luc Belingard Director |
SELL
Open market or private sale
|
Direct |
2,600
-14.31%
|
$699,400
$269.16 P/Share
|
|
May 03
2021
|
Jean Luc Belingard Director |
BUY
Exercise of conversion of derivative security
|
Direct |
2,600
+12.52%
|
$254,800
$98.49 P/Share
|
|
Apr 03
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
SELL
Payment of exercise price or tax liability
|
Direct |
452
-4.19%
|
$113,904
$252.67 P/Share
|
|
Apr 03
2021
|
Paul R Kirchgraber CEO, Covance Drug Development |
BUY
Exercise of conversion of derivative security
|
Direct |
1,010
+8.56%
|
-
|
|
Mar 30
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
812
-13.42%
|
$203,812
$251.88 P/Share
|
|
Mar 30
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Open market or private sale
|
Direct |
667
-11.76%
|
$167,417
$251.88 P/Share
|
|
Mar 27
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
687
-10.2%
|
$172,437
$251.58 P/Share
|
|
Mar 27
2021
|
Vaart Sandra D Van Der EVP, Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,310
+25.54%
|
-
|
|
Mar 27
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
SELL
Payment of exercise price or tax liability
|
Direct |
1,079
-15.98%
|
$270,829
$251.58 P/Share
|
|
Mar 27
2021
|
Mark S Schroeder EVP, Pres Diagnostics & COO |
BUY
Grant, award, or other acquisition
|
Direct |
2,413
+26.33%
|
-
|